Betnovate is a topical medication that contains betamethasone as its active ingredient. It is formulated as a 0.1 % cream and belongs to the skin-care therapeutic class of topical corticosteroids. In Hong Kong, Betnovate is a prescription product regulated by the Department of Health and is supplied under the brand name Betnovate.
Betamethasone is a synthetic glucocorticoid that mimics the anti-inflammatory actions of naturally occurring cortisol. When applied to the skin, it:
The anti-inflammatory effect usually begins within a few hours of application, with maximal clinical improvement observed after several days of consistent use. Because the cream is applied locally, systemic absorption is minimal in most patients, especially when used on limited skin areas.
Betnovate 0.1 % cream is approved in Hong Kong for the short-term treatment of inflammatory skin disorders, including:
The medication is intended for adults and children over 12 years of age; use in younger children should be directed by a specialist.
These reactions are usually transient and resolve after discontinuation or with reduced frequency of application.
If any of these occur, stop the cream and seek medical assessment promptly.
Topical betamethasone has limited systemic interaction potential, but caution is advised when used with:
Patients should inform their healthcare provider of all current medications, including over-the-counter and herbal products.
This article provides educational information about Betnovate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Betnovate 0.1 % cream is a mid- to high-potency corticosteroid, and prolonged facial use may increase the risk of skin thinning and visible blood vessels. Short-term application on small facial areas may be appropriate under medical supervision, but alternative lower-potency options are often preferred.
Typical courses last 7-14 days, aiming for the quickest control of symptoms. Extending treatment beyond two weeks should be reassessed by a clinician to avoid skin atrophy and systemic effects.
If a larger amount than prescribed is applied, gently wash the area with mild soap and water to remove excess product. Monitor for signs of irritation or systemic effects and contact a healthcare professional if symptoms develop.
Topical corticosteroids can be absorbed systemically, especially over large areas. Use in pregnancy, particularly in the third trimester, should only occur when the potential benefit outweighs the risk, and after discussion with a obstetrician or dermatologist.
Systemic weight gain is uncommon with topical use when applied as directed. However, extensive or prolonged application leading to significant systemic absorption could theoretically affect metabolism; this is rare.
Topical betamethasone generally does not appear in standard drug-testing panels. Nonetheless, competitive athletes should verify any anti-doping regulations with their governing bodies.
Occlusive dressings can increase skin absorption and raise the risk of systemic side effects. Covering should only be done if specifically instructed by a healthcare provider.
Betamethasone is considerably more potent than hydrocortisone, providing stronger anti-inflammatory effects but also carrying a higher risk of skin atrophy when misused. Choice of steroid depends on the severity of the condition and physician recommendation.
The formulation typically contains emollient bases, preservatives, and stabilizers designed to enhance skin penetration and product stability. Exact inactive components can be found on the product’s package insert.
Do not pour the cream down the drain. Seal the container and return it to a pharmacy drug-take-back program or follow local hazardous-waste disposal guidelines.
